多西他赛联合奈达铂和顺铂治疗晚期非小细胞肺癌临床观察  

Docetaxel combined with nedaplatin and cisplatin in treatment of advanced non-small cell lung cancer

作　　者：陈雷[1] 陈建章[1] 尤传文[1] 刘金平[1] 

机构地区：[1]南京鼓楼医院集团宿迁市人民医院肿瘤科,江苏宿迁223800

出　　处：《实用肿瘤杂志》2012年第1期77-79,共3页Journal of Practical Oncology

摘　　要：目的观察多西他赛联合双铂方案治疗晚期非小细胞肺癌的近期疗效及不良反应。方法 60例患者随机分为治疗组和对照组,每组30例。治疗组:多西他赛75 mg/m2,分别于第1、8天给药;顺铂(PDD)15 mg/(m2.d),d1-3天;奈达铂(NDP)50 mg/m2,d5;对照组:多西他赛75 mg/m2,分别于第1、8天给药;顺铂(PDD)25mg/(m2.d),d1-3天。21天为1周期。结果治疗组:CR 2例,PR 12例,SD 15例,PD 1例,有效率(RR)为46.7%(14/30);对照组:CR 1例,PR 12例,SD 15例,PD 2例,有效率(RR)43.3%(13/30),两组有效率比较差异无统计学意义(P>0.05);对照组呕吐的发生率明显高于治疗组(P<0.05)。白细胞减少治疗组为96.7%,对照组为93.3%(P>0.05)。血小板减少治疗组为73.3%,对照组为30.0%(P<0.05)。结论多西他赛联合双铂方案治疗晚期非小细胞肺癌的疗效确切,不良反应可耐受。Objective To observe the efficacy and adverse reaction of docetaxel combined with two platinum in the treatment of patients with advanced non-small cell lung cancer（NSCLC）. Methods Sixty cases were randomly devided into two groups and each group had 30 cases.In treating group,patients received docetaxel 75 mg/m2,d 1,d 8;PDD 15 mg/（m2·d）,d1-3,NDP 50 mg/m2,d5;in control group,patients received docetaxel 75 mg/m2,d1,d8;PDD 25 mg/（m2·d）,d1-3;21 days as one cycle. Results In treating group,there were CR in 2 cases,PR in 12,SD in 15,PD in 1.The rate of RR was 46.7%（14/30）.In control group,there were CR in 1 case,PR in 12,SD in 15,PD in 2.The rate of RR was 43.3%（13/30）.The rate of RR was similar in the two groups（P〉0.05）.The rate of vomiting in the control group was higher than in the treating group（P〉0.05）.The rate of decrease of WBC was 96.7% in the treating group and 93.3% in control group（P〈0.05）.The rate of decrease of platelet was 73.3% in the treating group and 30.0% in control group（P〈0.05）. Conclusions There are certain curative effect of combination chemotherapy with docetaxel and two platinum for treatment of advanced non-small cell lung cancer（NSCLC）,and the side effect can be tolerated.

关 键 词：癌 非小细胞肺 药物疗法 多西他赛/治疗应用 顺铂/治疗应用 奈达铂/治疗应用 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]